TY - JOUR
T1 - Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells
T2 - Improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2
AU - Escudier, B.
AU - Farace, F.
AU - Angevin, E.
AU - Charpentier, F.
AU - Nitenberg, G.
AU - Triebel, F.
AU - Hercend, T.
PY - 1994/1/1
Y1 - 1994/1/1
N2 - Treatment with interleukin-2 (IL2) induces clinical responses in 15-30% of metastatic renal cell carcinoma (MRCC) patients, with mainly partial responses. In order to improve clinical response, we decided to treat partial response patients from a previous IL2 treatment with a second course of IL2 associated with lymphokine-activated natural killer (LANAK) cells. 10 patients who underwent PR after an IL2 protocol (24 × 106 U/m2/day, 2 days a week for 5 weeks, either alone or with interferon-γ) subsequently received a combination of high-dose IL2 (16-20 × 106 U/m2/day, 2 days a week) and LANAK cell infusions. Four complete responses were obtained, and 2 additional patients whose tumour mass was further reduced achieved complete response following surgery. These results support the view that initial responses obtained with primary IL2 courses can be improved by complementary treatments. The potential role of cellular immunotherapy and, more particularly, of LANAK cells as an effective procedure to further reduce tumour burden in patients responsive to IL2 will have to be assessed in randomised studies.
AB - Treatment with interleukin-2 (IL2) induces clinical responses in 15-30% of metastatic renal cell carcinoma (MRCC) patients, with mainly partial responses. In order to improve clinical response, we decided to treat partial response patients from a previous IL2 treatment with a second course of IL2 associated with lymphokine-activated natural killer (LANAK) cells. 10 patients who underwent PR after an IL2 protocol (24 × 106 U/m2/day, 2 days a week for 5 weeks, either alone or with interferon-γ) subsequently received a combination of high-dose IL2 (16-20 × 106 U/m2/day, 2 days a week) and LANAK cell infusions. Four complete responses were obtained, and 2 additional patients whose tumour mass was further reduced achieved complete response following surgery. These results support the view that initial responses obtained with primary IL2 courses can be improved by complementary treatments. The potential role of cellular immunotherapy and, more particularly, of LANAK cells as an effective procedure to further reduce tumour burden in patients responsive to IL2 will have to be assessed in randomised studies.
UR - http://www.scopus.com/inward/record.url?scp=0027957085&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(94)90460-X
DO - 10.1016/0959-8049(94)90460-X
M3 - Article
C2 - 7654433
AN - SCOPUS:0027957085
SN - 0959-8049
VL - 30
SP - 1078
EP - 1083
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 8
ER -